Interest in psychedelic medicines has accelerated in recent years, and new research focusing on dimethyltryptamine (DMT), the main psychoactive compound found in ayahuasca, has been found to have positive results. Early clinical findings suggest the compound may offer meaningful benefits for people living with depression, particularly those who have not responded well to traditional antidepressants. Unlike conventional therapies that often require daily dosing and several weeks before improvements are noticed, DMT appears capable of producing rapid
changes in mood and outlook after a single, carefully supervised treatment session. This has led researchers and investors alike to reconsider how depression might be treated in the future.
DMT’s effects appear to stem from a combination of biological and psychological mechanisms rather than a single pharmacological pathway. At a molecular level, the compound strongly activates serotonin 5-HT2A receptors, which play a key role in perception, mood regulation, and cognition. Activation of these receptors temporarily alters communication between brain regions and reduces the neurological activity that is often linked to the self-focused thinking and persistent rumination seen in depression. By loosening these rigid patterns of activity, patients may experience a temporary increase in cognitive flexibility, allowing them to reassess entrenched thoughts and emotional responses. Beyond serotonin signalling, DMT also interacts with sigma-1 receptors involved in cellular stress regulation and neuroprotection. This interaction is associated with increased production of neurotrophic factors such as BDNF, supporting neuronal repair and synaptic growth. Researchers believe this surge in neuroplasticity may help explain why psychological improvements can persist well beyond the acute psychedelic experience, particularly when treatment is combined with therapeutic support.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Clinical development in this area is expanding steadily. According to GlobalData’s Clinical Trials Database, there are 39 trials listed that are investigating DMT and its effects on depression. Approximately 56% of these studies have already been completed. Around 15% remain ongoing and are actively recruiting participants, while roughly 10% are planned but not yet initiated. The remaining 18% have been suspended, terminated, or withdrawn.
Geographically, activity is concentrated in a small number of research centres. The UK leads with about 44% of all trials, followed by the Netherlands with roughly 18% and the US with around 13%. Key sponsors include GH Research, Beckley Psytech, HELUS Pharma, and Biomind Labs. Together, these trends suggest that DMT-based therapies are gradually moving from niche academic interest toward structured clinical development, positioning psychedelics as a potentially important new category within the depression treatment landscape. As regulatory frameworks evolve and larger, later-stage studies emerge, the industry will be watching closely for confirmation of durability and effectiveness across mainstream mental health healthcare systems.
